Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aura Biosciences Inc ( (AURA) ) just unveiled an update.
On April 30, 2026, Aura Biosciences entered into a stock purchase agreement with Matrix Capital Management Master Fund to repurchase up to 6,922,870 shares of its common stock, which represented Matrix’s entire 10.8% stake as of April 15, 2026. The shares are to be repurchased at $5.64 per share, matching the price in an underwritten equity offering announced on May 4, 2026, and will become authorized but unissued shares, with the transaction reviewed and approved by the audit committee and board.
The stock repurchase is conditioned on the successful closing of the equity offering and other customary conditions, and there is no assurance it will be completed as planned. Separately, Aura disclosed preliminary, unaudited cash, cash equivalents and marketable securities of approximately $114.7 million as of March 31, 2026, providing investors with an early view of its liquidity ahead of formal quarterly reporting.
The most recent analyst rating on (AURA) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, expanding losses, and increasing cash burn). This is partially offset by improving technical positioning above key moving averages and positive corporate updates around Phase 3 enrollment progress and stated liquidity runway, while valuation remains challenged due to ongoing losses and no dividend support.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences, Inc. is a biotechnology company focused on developing novel therapies, with its common stock actively held by institutional investors. The company operates in the life sciences sector and accesses capital markets through underwritten equity offerings to fund its corporate and development activities.
Average Trading Volume: 270,276
Technical Sentiment Signal: Hold
Current Market Cap: $450M
For a thorough assessment of AURA stock, go to TipRanks’ Stock Analysis page.